NCT03493542View on ClinicalTrials.gov

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

PHASE3CompletedINTERVENTIONAL
Enrollment

766

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
Interventions
BIOLOGICAL

V501

0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6

Trial Locations (1)

529600

Yangchun Center For Disease Prevention And Control ( Site 0003), Yangchun

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03493542 - A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) | Biotech Hunter | Biotech Hunter